Overview

A Study to Compare the Efficacy, Safety and Tolerability of Selomax With Its Individual Components

Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
This is a randomised, open-label; parallel group, multicentric study comparing the efficacy and safety of fixed-dose-combinations of Metoprolol XL plus Amlodipine with individual components of the combination. SelomaxTM50/5 will also be compared with SelomaxTM 25/2.5 in lowering of BP (SBP and DBP) in Indian patients with essential hypertension.Male and female patients of essential hypertension aged between 18-80 years will be studied. The patients should not have a history of prior cardiovascular disease.
Phase:
Phase 4
Details
Lead Sponsor:
AstraZeneca
Collaborator:
St. John's Research Institute
Treatments:
Amlodipine
Metoprolol